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Abstract 
Purpose: To determine the effectiveness and safety of statins in ischemic heart disease (IHD) patients 
in a Malaysian tertiary hospital.  
Methods: This cross-sectional observational study was conducted at Universiti Kebangsaan Malaysia 
(UKM) Medical Center, Kuala Lumpur, Malaysia and patients were included if they were diagnosed with 
IHD and treated on statins for three months, or had IHD with no statins prescribed.   
Results: A total of 72 patients admitted to the medical ward due to IHD were enrolled in this study. Fifty 
three of them were statin users and 19 patients had no history of statin treatment. The most commonly 
used statin was lovastatin (n = 42, 79.2 %), atorvastatin (n = 5, 9.4 %), simvastatin (n = 3, 5.7 %) and 
rosuvastatin (n = 3, 5.7 %). Risk factors found in the study population were dyslipidaemia (n = 52, 72 
%), hypertension (n = 58, 80.1 %), diabetes (n = 36, 50 %), advanced age (n = 63, 87.5 %), smoking (n 
= 19, 26.4 %) and family history (n = 16, 22.2 %). Patients that were on statin were more likely to 
achieve targeted LDL-C levels compared to those that did not achieve LDL-C levels (χ2 = 7.25, p = 
0.007). There were also no difference in liver enzyme values between statin users and non-statin users.  
Conclusion: This study provides information regarding safety and efficacy of statins in the local 
population and the need for a more stringent approach in achieving targeted lipid levels in IHD patients. 
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Ischemic heart disease (IHD) is a rapidly 
increasing problem around the world [1]. It is also 
the leading cause of death in Malaysia, 
accounting for 2,556 deaths in 2002 [2]. Several 
risk factors have been identified that increases 
the likelihood of IHD. The established risk factors 
based on the Wilson study results include current 
smoking, hypertension, dyslipidemia, diabetes, 
male sex and advanced age [3]. The presence of 
these risk factors contributes to the basic 
pathogenesis of atherosclerosis. Therefore, 
reducing the risk factors decreases the likelihood 
of disease progression and coronary morbidity as 
well as mortality. 
 
Pharmacological intervention for primary and 
secondary prevention of IHD is by lowering 
cholesterol level. This is to prevent 
artherosclerosis that may lead to incidence of 
cardiovascular events. In order to achieve the 
targeted goal, HMG-CoA reductase inhibitor 
(statins) have been indicated as the first line drug 
of choice in various guidelines [1]. The available 
statins include atorvastatin, fluvastatin, 
lovastatin, rosuvastatin, pravastatin, pitavastatin 
and simvastatin. The mechanism of action of 
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statins is inhibition of the rate-limiting enzyme in 
cholesterol synthesis, HMG-CoA reductase. 
Nevertheless, each statin is different in terms of 
chemical structure and efficacy in lipid reduction. 
The differences in absorption, plasma protein 
binding, excretion and solubility therefore exhibit 
variable dose-related efficacy in reducing LDL-C 
[4].  
 
The primary effect of statin therapy is LDL-C 
reduction [5]. Reduction in LDL-C level will 
reduce the progression of atherosclerotic plaque, 
reduce mortality and promote revascularization in 
patients with IHD [6]. The response to statin 
therapy also varies between each individual. 
However, despite the difference in effect and 
response to different statins, LDL-C reduction 
can be expected to range from 20 to 63 % [7]. 
Recommended therapeutic doses, which 
typically reduce LDL-C by 30 to 45 %, are 
atorvastatin 10 to 20 mg, fluvastatin 40 to 80 mg, 
lovastatin 40 mg, pitavastatin 1 to 4 mg, 
pravastatin 40 mg, rosuvastatin 10 mg, and 
simvastatin 20-40 mg [7]. Apart from LDL-C 
reduction, statin has also been reported to 
elevate HDL-C levels [5]. The elevations in HDL-
C are typically more moderate, with an 
approximate 5 to 15 % increase. On the other 
hand, triglyceride levels can be reduced by 10 to 
37 % with statins [7]. 
 
In view of the variety in effectiveness of the 
statins, inter-individual response should be 
considered when initiating the drug. Therefore, 
this study aims to look at the effectiveness of 
different statins in reducing lipid levels in IHD 




Study design  
 
This study was conducted as a prospective 
cross-sectional, observational study in UKM 
Medical Center. Patients included in this study 
were patients admitted to the medical ward due 
to incidence of IHD. Samples were selected from 
the ward admission record. Patients were 
included in the study if they were 18 years and 
above and diagnosed with IHD and were either 
on statins for the past three months prior to 
admission, or have not been on statins at all. 
Patients with incomplete data were excluded 
from the study. The study was approved by UKM 
Research Ethics Committee, The National 
University of Malaysia (no. UKM 1.5.3.5/244/NF-
013-14/Dr Endang) and was carried out in 
accordance with International Conference on 
Harmonisation of Good Clinical Practice 




Patients with IHD were divided into statin and 
non-statin groups. In this study, the use of statin 
is defined as patients taking statins three months 
prior to hospitalization.  Information on type, dose 
and duration of statin treatment were collected. 
Lipid profile (LDL-C, HDL-C, triglyceride and total 
cholesterol) and liver enzymes (ALT and ALP) 
were also collected. Other data collected were 
age, gender, height, weight, race, medical 
history, medication history, social history and 
family history.  
 
Data analysis  
 
All data collected were analyzed using SPSS 
version 21.0 software package. Descriptive 
analysis was conducted to observe for frequency 
in selected variables. Categorical variables were 
presented as absolute (n) and relative 
frequencies (percentages) while numerical data 
were presented as mean values and standard 
deviations. The differences in categorical 
variables were compared using Pearson Chi 
Square (χ2) and Fisher’s Exact Test. The 
differences in continuous variables were 
examined by independent student t-test for two 
independent variables and a one way analysis of 
variance (ANOVA) for more than three 
independent variables. All statistical values were 






Out of 72 patients with IHD, 53 (73.6 %) patients 
were on statins 3 months prior to admission while 
19 (26.4 %) patients were not on any statin 
treatment prior to admission (Table 1). The age 
of patients ranged from 35 to 87 years old with a 
mean age of 61.76 ± 11.49 years. Patients with 
IHD that were not on statin prior to admission 
was significantly younger than those that were on 
statins (t(20) = 2.576, p = 0.012). There were 
more males on statin use compared to females 
(χ2 = 4.95, p = 0.026). More patients were on 
statins if they were noted to have a history of IHD 
compared to those that did not have a history of 
IHD (χ2 = 14.17, p = 0.0001).  The most 
commonly used statin was lovastatin (n = 42, 
79.2 %), atorvastatin (n = 5, 9.4 %), simvastatin 
(n = 3, 5.7 %) and rosuvastatin (n = 3, 5.7 %). 
Doses of the statins used in the study population 
were observed to be low to moderate doses [5]. 
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Risk factors present in the study population were 
dyslipidaemia (n = 52, 72 %), hypertension (n = 
58, 80.1 %), diabetes (n = 36, 50 %), advanced 
age (n = 63, 87.5 %), smoking (n = 19, 26.4 %) 
and family history (n = 16, 22.2 %). 
 
Effectiveness of statins 
 
During the study period, 52 (72.2 %) patients had 
dyslipidemia; with high LDL-C, high TG, high 
total cholesterol, low HDL-C or a combination of 
2 to 3 lipid abnormalities. From a total of 53 
patients on statin, 33 (62 %) patients achieved 
target LDL-C goal, 34 (64.2 %) patients achieved 
target triglyceride goal and 39 patients (73.6 %) 
achieved the target HDL-C goal as 
recommended by NCEP ATP III. Patients that 
were on statin were more likely to achieve 
targeted LDL-C levels compared to those that did 
not achieve LDL-C levels (χ2 = 7.25, p = 0.007). 
There was no difference in achieved target lipid 
levels between race and gender. There was also 
no correlation between age and weight with 
levels of lipids achieved. 
 
Safety of statins 
 
No adverse reactions were reported during the 
use of statins in this study population. However, 
liver function tests were examined in patients 
included in the study. It was found that the levels 
of aminotransferase (ALT) and alkaline 
phosphatase (ALP) were not-significant different 
between the statin and non-statin users. 
 
Table 1: Demographic data of the study population (N=72) 
 
Variable Statin users Total 
 
(N = 72) Yes 
(n = 53) 
No 
(n = 19) 
Age, years (mean ± SD) 63.77 ±10.81 56.16 ± 11.73 61.76 ± 11.49 
Weight, kg (mean ± SD) 69.23 ± 11.57 63.42 ± 10.95 67.71 ± 1.6 









































Table 2: Lipid levels of the study population on admission (N = 72) 
 
Lipid levels Statin users aP-value 
 
 Yes 
(n = 53) 
No 
(n = 19) 
Total cholesterol  
(> 5.18 mmol/L) 










(> 3.4 mmol/L) 
(≤ 3.4 mmol/L) 
 
20 (38%) 







(> 1.7 mmol/L) 
(≤  1.7 mmol/L) 
 
19 (36%) 







(≤ 1 mmol/L) 
(> 1 mmol/L) 
 
14 (26%) 
 39 (74%) 
 
8 (42%) 
 11 (58%) 
 
0.203 
* P < 0.05 considered significant; a  Chi-squared test 
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Table 3: Liver enzymes of the study population on admission (N=67) 
 
Lipid level Statin users n(%) aP-value 
 
 Yes (n = 48) 
No 
(n = 19) 
ALT 
(≤ 44 U/L) 


























Statins are the most widely used drugs around 
the world. The use of statins, in particular is 
highly recommended in IHD patients. This is 
especially true in view of the effectiveness in 
reducing lipid levels in this group of patients [9]. 
There have been numerous studies 
demonstrating the lipid lowering effects of statin 
in various patient populations [2,4]. However, its 
effects have been notably varied with inter-
individual differences [2]. The aim of this present 
work is to evaluate the effectiveness of statins in 
IHD patients in the local population was 
successful. In general, the number of male IHD 
patients was higher than female, which was 
similarly observed in previous studies [2,3]. 
 
Several major risk factors were also identified in 
the present study population such as smoking, 
hypertension, dyslipidemia, diabetes and 
advanced age [10]. Early identification of these 
risk factors in high risk patients as well as 
patients with known IHD is beneficial. Early and 
vigorous approach in risk-factor reduction should 
be performed in order to reduce IHD 
complications. Interventions include non-
pharmacological approach with therapeutic 
lifestyle modification such as smoking cessation, 
dietary modification and physical activity as well 
as drug therapy to treat hypertension, diabetes 
and dyslipidemia [10].  
 
Dyslipidemia is common amongst patients 
admitted due to IHD [5]. Early screening of lipid 
levels in high risk groups is essential in order to 
detect lipid abnormalities. The NCEP–ATP III 
recommends beginning screening of all adults at 
age 20, regardless of cardiovascular risk profile 
[11]. Early screening promotes healthy behavior 
and increases public awareness of cholesterol 
levels [12]. The most prevalent lipid 
abnormalities in this current work were high total 
cholesterol followed by high LDL-C levels. The 
lack in achieving LDL-C levels is a common risk 
factor in incidences of IHD complications. As 
structural homologues of 3-hydroxy 3-
methylglutaric acid, statins competitively inhibit 
HMG-CoA reductase, the last regulated step in 
the synthesis of cholesterol. These drugs lower 
serum LDL cholesterol concentrations by up-
regulating LDL-receptor activity as well as 
reducing the entry of LDL into the circulation [13].  
Elevated LDL-C has been demonstrated to 
correlate with recurrent incidence of cardiac 
events [1]. Indeed, it is important to note that in 
the present study, there was a strong association 
between statin use and levels of LDL-C. It was 
noted that those that were not on statins were 
more likely to have higher levels of LDL-C 
compared to patients with normal LDL-C levels. 
Thus, statin treatment in the local population is 
significantly associated with a better LDL-C level.  
Despite the use of statin, it was noted that some 
patients failed to achieve target lipid goal. Many 
factors and conditions may contribute to this 
failure. Despite the low to moderate doses of 
statin used [5], it has been reported that low HDL 
cholesterol persisted in more than 50 % of high-
risk patients despite statin usage [14]. In this 
study several factors may have contributed to the 
failure of treatment. The effect of smoking in 
increasing triglyceride level has been reported. 
This is due to secretion of cathecolamines which 
cause lipolysis. Effect of smoking in altering lipid 
level differs between ethnic groups with higher 
lipid levels observed in Asian smokers compared 
to African smokers [15].  
 
Plasma levels of HDL-C have also been shown 
to have a strong genetic basis with heritability 
estimates of 40-60 % [16]. Therefore, it can be 
suggested that in patients with a family history of 
premature CAD, combination therapy of statins 
with other agents such as fibrates and niacins 
can be used [17]. Fibrates mainly affect HDL-
cholesterol level by stimulating lipoprotein-lipase 
activity and thereby facilitates the clearance of 
chylomicrons and very low density lipoproteins 
from the plasma. This makes fibrates particularly 
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suitable for the subgroup of patients who have 
low HDL-cholesterol levels [18].  
 
Besides this, non-pharmacological strategies for 
the treatment of dyslipidemia should also be 
included. Inadequate counseling about proper 
diet and exercise can also contribute to the 
failure in reaching target goals. Combination 
therapies of diet and exercise interventions are 
efficacious [19]. Combination lifestyle treatments 
are particularly advantageous because diet and 
exercise elicit complementary effects on lipid 
profiles.  
 
The use of statins is relatively safe with adverse 
reactions being relatively mild and often 
transient. The most common adverse effects of 
statins are gastrointestinal upset, muscle aches, 
and hepatitis [5]. Rarer problems associated with 
statins are myopathy [13]. However, one of the 
most important adverse effects associated with 
statins as a class of drugs is the asymptomatic 
increase in liver transaminases as well as 
myopathy [5]. The likelihood of elevated ALT and 
ALP levels that can cause serious adverse 
effects to the liver system however is not 
common. Indeed this is similarly observed in the 
present work. Previous studies have also 
reported very minimal incidence (about 1 %) of 
elevated liver enzymes with the majority 
occurring during three months of treatment.  
 
The incidence of elevated liver enzymes have 
also been shown to be dose related [5,20]. The 
lack of serious liver abnormalities in the current 
work can be attributed to the low dose of statin 
use in the present population. Furthermore, statin 
therapy at low to moderate doses has been 
previously found to not be associated with a 
significant risk of liver function abnormalities [21]. 
It is suggested that marked elevation of liver 
enzymes are rare and are most likely to occur 
when potential drug interactions or comorbidities 
are present (including preexisting liver disease) 
or the highest dose of statin is used [5,22].  
 
Limitations of the study 
 
In this study, other factors that may also 
contribute to the outcomes observed, such as 
diet intake, patient’s lifestyle and compliance 
level, were not measured. A small sample size 
and unequality distribution of samples in every 
category may also be one of the drawbacks in 




The study was able to identify the effectiveness 
and safety of statins in IHD patients of the local 
population. However, it should be noted that 
there were a number of patients that were not 
prescribed statins despite being diagnosed with 
IHD. Further work should be performed to 
identify reasons statins were not prescribed to 
these patients. Healthcare professionals should 
also perform a much more stringent approach in 
monitoring statin use and stress the need to 
adhere to both pharmacological and non-
pharmacological treatments to ensure the 
effectiveness of achieving the required lipid 
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